Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus
Sponsor: GlaxoSmithKline
This PHASE3 trial investigates Diabetes Mellitus, Type 2 and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Dec 2017 [monthly]
Completed PHASE3
First recorded
Jan 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
's-Hertogenbosch, Netherlands, Aberdeen, United Kingdom, Acquaviva Delle Fonti (BA), Italy, Airdrie, United Kingdom, Albaida (Valencia), Spain, Albany, United States, Alben, France, Albuquerque, United States, Ann Arbor, United States, Anniston, United States and 404 more location s